EIF4E and leukemia: Furthermore, we found that the proteasome inhibitor MG132 strongly blocked the HHT-induced decrease in p-eIF4E levels in leukemia cells (Fig. 4B), suggesting that HHT treatment triggers the proteasome-dependent degradation of p-eIF4E protein.